香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6185） 截至2023年12月31日止的年度業績公告 康希諾生物股份公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈本公司及 其附屬公司截至2023年12月31日止年度之經審計合併年度業績。 本業績公告列載本公司截至2023年12月31日止年度報告全文，並符合香港聯合交 易所有限公司證券上市規則中有關年度業績初步公告須附載的資料之要求。董事 會及董事會下轄的審計委員會已審閱並確認本業績公告。 本業績公告於香港聯合交易所有限公司網站( www.hkexnews.hk )及本公司網站 ( www.cansinotech.com )刊登。本公司截至2023年12月31日止年度的年度報告將在 適當時候寄發予本公司股東，並於上述網站上刊登。 承董事會命 康希諾生物股份公司 董事長 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6185） 截至2023年9月30日止九個月的第三季度報告 本公告由康希諾生物股份公司（「本公司」，連同其附屬公司統稱「本集團」）根據香 港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)及13.10B條以及香 港法例第571章證券及期貨條例第XIVA部內幕消息條文（定義見上市規則）發佈。 茲載列本集團截至2023年9月30日止九個月（「報告期」）未經審計業績報告（「第三 季度報告」）。第三季度報告中所載財務資料乃根據中國企業會計準則編製，且未 經本集團核數師審計。本公司潛在投資者及股東在買賣本公司股份時務請審慎行 事。 第三季度報告以中英文版本編製。倘出現任何歧義，概以第三季度報告中文版本 為準。 | --- | --- | --- | --- | |------- ...

2023 中期報告 （於中華人民共和國註冊成立的股份有限公司） 股份代號：6185 2023 中期報告 目錄 公司資料 02 財務概要 04 管理層討論及分析 05 其他資料 20 獨立核數師報告 29 簡明合併損益及其他綜合收益表 30 簡明合併財務狀況表 31 簡明合併權益變動表 33 簡明合併現金流量表 34 簡明合併財務報表附註 35 釋義 63 公司資料 | --- | --- | |---------------------------------------------|----------------------------------| | | | | 董事會 | 提名委員會 | | 執行董事 | 劉建忠先生 （主席） | | | Xuefeng YU 博士 | | Xuefeng YU 博士 | 韋少琨先生 桂水發先生 | | （主席、首席執行官兼總經理） | | | Shou Bai CHAO 博士 （首席運營官兼副總經理） | 梁頴宇女士 | | 朱濤博士 | 監事 | | （首席科學官兼副總經理） | | | Dongxu QIU 博士 （執行副總裁兼副總經理） | 李江峰女士 （主 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6185） 中期業績公告 截至2023年6月30日止六個月 康希諾生物股份公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈本公司及 其附屬公司截至2023年6月30日止六個月的未經審核中期業績。 本業績公告列載本公司截至2023年6月30日止六個月中期報告全文，並符合香港 聯合交易所有限公司證券上市規則中有關中期業績初步公告須附載的資料之要 求。董事會及董事會下轄的審計委員會已審閱並確認本業績公告。 本業績公告於香港聯合交易所有限公司網站( www.hkexnews.hk)及本公司網站 ( www.cansinotech.com)刊登。本公司截至2023年6月30日止六個月的中期報告將 在適當時候寄發予本公司股東，並於上述網站上刊登。 | --- | --- | --- | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6185） 截至2023年3月31日止三個月的第一季度報告 本公告由康希諾生物股份公司（「本公司」，連同其附屬公司統稱「本集團」）根據香 港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)及13.10B條以及香 港法例第571章證券及期貨條例第XIVA部內幕消息條文（定義見上市規則）發佈。 茲載列本集團截至2023年3月31日止三個月（「報告期」）未經審計業績報告（「第一 季度報告」）。第一季度報告中所載財務資料乃根據中國企業會計準則編製，且未 經本集團核數師審計。本公司潛在投資者及股東在買賣本公司股份時務請審慎行 事。 第一季度報告以中英文版本編製。倘出現任何歧義，概以第一季度報告中文版本 為準。 | --- | --- | --- | --- | --- | |- ...

Financial Performance - In 2022, the company reported a revenue of RMB 1,031,041 thousand, a significant decrease of 76.0% compared to RMB 4,299,702 thousand in 2021[21]. - The operating loss for 2022 was RMB (1,368,742) thousand, compared to an operating profit of RMB 1,911,612 thousand in 2021[21]. - The net loss for the year was RMB (964,757) thousand, a decline from a profit of RMB 1,907,086 thousand in the previous year[21]. - The total equity as of December 31, 2022, was RMB 7,245,602 thousand, down from RMB 8,547,884 thousand in 2021[21]. - Total revenue for the year ended December 31, 2022, was approximately RMB 1,031.0 million, a decrease of 76.0% from RMB 4,299.7 million in 2021[45]. - Gross loss for the year ended December 31, 2022, was approximately RMB 186.6 million, compared to a gross profit of RMB 3,001.9 million in 2021[47]. - Other income increased by 158.3% to approximately RMB 156.9 million for the year ended December 31, 2022, from RMB 60.8 million in 2021[48]. - Sales expenses rose to approximately RMB 266.6 million for the year ended December 31, 2022, from RMB 105.8 million in 2021[49]. - Administrative expenses increased by 20.0% to approximately RMB 278.1 million for the year ended December 31, 2022, from RMB 231.8 million in 2021[50]. - Research and development expenses decreased by 11.4% to approximately RMB 778.3 million for the year ended December 31, 2022, from RMB 878.7 million in 2021[51]. - Financial income increased significantly to approximately RMB 184.7 million for the year ended December 31, 2022, from RMB 25.2 million in 2021, mainly due to foreign exchange gains[53]. - The company's inventory decreased significantly to approximately RMB 677.8 million as of December 31, 2022, from RMB 875.6 million as of December 31, 2021, primarily due to inventory write-downs[57]. - Accounts receivable increased significantly to approximately RMB 855.5 million as of December 31, 2022, from RMB 157.9 million as of December 31, 2021[58]. - The company's intangible assets increased to approximately RMB 162.6 million as of December 31, 2022, from RMB 99.8 million as of December 31, 2021, mainly due to the increase in non-patented technology assets[56]. - Accounts payable decreased significantly from approximately RMB 842.6 million as of December 31, 2021, to approximately RMB 253.1 million as of December 31, 2022, reflecting a reduction in purchase volume[60]. - Other payables and accrued expenses increased by 15.7% from approximately RMB 684.5 million as of December 31, 2021, to approximately RMB 791.9 million as of December 31, 2022, primarily due to an increase in marketing service fees and other payables to suppliers[62]. - Cash and cash equivalents decreased by 37.8% from approximately RMB 5,456.9 million as of December 31, 2021, to approximately RMB 3,394.8 million as of December 31, 2022, mainly due to reduced cash inflow from sales revenue[63]. - Current assets were approximately RMB 7,730.2 million as of December 31, 2022, down from RMB 9,289.8 million as of December 31, 2021[63]. - The company has no significant contingent liabilities that could adversely affect its business or financial condition as of December 31, 2022[66]. - The company is in a net cash position as of December 31, 2022, making the debt-to-equity ratio not applicable[70]. - The company reported a significant increase in revenue, achieving a total of $X million for the fiscal year, representing a Y% growth compared to the previous year[78]. - The company’s revenue growth and strategic initiatives are supported by a strong management team with diverse backgrounds in finance, business development, and regulatory compliance[84]. - The company’s financial reports for the year ending December 31, 2022, were presented alongside the board report, indicating a commitment to transparency in financial performance[127]. - The company did not recommend a final dividend for the reporting period, compared to RMB 197.7 million in 2021[129]. Vaccine Development and Innovation - The company launched the world's first inhalable COVID-19 vaccine, Convidecia Air, in October 2022, which received significant media attention[22]. - The company is developing new vaccines, including a bivalent recombinant COVID-19 vaccine and an mRNA vaccine, with promising safety and immunogenicity profiles[22]. - Convidecia has been widely administered in many countries, contributing to global public health efforts[22]. - The company is collaborating with local partners in Malaysia and Indonesia for vaccine formulation, production, and distribution[22]. - The inhaled recombinant COVID-19 vaccine, Kweisha® Mist, is the world's first aerosolized vaccine that provides triple protection without the need for injections[28]. - Kweisha® received emergency use authorization in multiple countries, including Mexico, Pakistan, and Hungary, and was included in the WHO's emergency use listing in September 2022[28]. - The company is actively collaborating with international partners to establish local production facilities and subsidiaries to enhance global coordination[23]. - The pipeline includes several vaccines in various stages of clinical trials, such as the CS-2023 meningococcal vaccine and the CS-2028 polyvalent pneumococcal conjugate vaccine[26][27]. - The company is focused on developing high-quality vaccines to meet the unmet medical needs in the global market[25]. - Kweisha® and Kweisha® Mist are recommended as second booster vaccines in China as of December 2022[28]. - The company has established a comprehensive marketing and supply system in China since the launch of multiple vaccine products in 2022[23]. - The company’s proprietary adenovirus vector vaccine, Kweisha®, is the first of its kind to enter clinical stages globally, with positive results published in The Lancet for Phase I, II, and III trials[29]. - A Phase IV trial published in Nature Medicine showed that Kweisha® as a booster after an inactivated COVID-19 vaccine demonstrated better efficacy compared to homologous boosters, establishing a strong foundation for emergency use approvals worldwide[29]. - Kweisha® Mist, a novel delivery method, has shown to induce triple immune protection with a dosage only 1/5 of the intramuscular Kweisha®, enhancing its appeal due to its pain-free and convenient administration[29]. - The company announced ongoing clinical studies for Kweisha® and Kweisha® Mist in various age groups, with positive interim data supporting the upgrade of immunization strategies[29]. - The company’s meningococcal vaccine, Manhaixin®, received approval in December 2021, becoming China’s first MCV4 vaccine, filling a significant gap in high-end vaccines in the country[31]. - Manhaixin® has been commercialized and penetrated nearly 30 provinces in China, with a growing market presence[31]. - The company’s Ad5-EBOV vaccine, approved for emergency use in 2017, is recognized for its stability and safety, although it is not expected to make significant commercial contributions in the near term[32]. - The mRNA COVID-19 vaccine CS-2034 has shown promising interim data, with a geometric mean titer (GMT) of 407 against the Omicron BA.5 variant, which is 29 times higher than that of inactivated vaccines[33]. - The company has initiated Phase Ib clinical trials for its innovative non-serotype pneumococcal vaccine, PBPV, which aims to provide broader protection than existing serotype vaccines[35]. - The company plans to begin the new drug registration application process for the improved PCV13i vaccine in 2023 following the completion of Phase III trials[34]. - The company is developing a DTcP vaccine for infants in China, which contains three types of pertussis antigens, providing better protection compared to the existing vaccine with two antigens[36]. - The Phase I clinical trial for the DTcP vaccine was completed in 2020, but development has been delayed due to resource allocation to Ad5-nCoV, with Phase III trials expected to start in 2023[36]. - The company is also working on a DTcP booster vaccine for children aged 4 to 6, with no approved vaccines currently available in China for this age group, indicating unmet demand[37]. - The company has initiated communication with the National Medical Products Administration for clinical trial applications for the adolescent and adult Tdcp vaccine, which is expected to progress further[38]. - A novel tuberculosis booster vaccine is under development, showing good safety and tolerance in Phase I trials, with plans for further clinical trial evaluations[39]. - The company is establishing an mRNA technology platform in Shanghai, aiming to develop innovative preventive vaccines with significant advantages over traditional platforms[41]. - The company has established a vaccine production base with an annual capacity of nearly 100 million doses, designed and operated in compliance with national and international GMP standards[71]. - The company has been involved in various international clinical trials for its COVID-19 vaccine, with successful approvals in countries like Pakistan, Mexico, Russia, and Chile[83]. - The company has made significant investments in research and development, focusing on new vaccine technologies and expanding its product pipeline[83]. Corporate Governance and Management - The board consists of five executive directors, three non-executive directors, and four independent non-executive directors[88]. - The company has adopted all applicable provisions of the corporate governance code as per the Hong Kong Listing Rules Appendix 14[86]. - The company confirms that all directors and supervisors complied with the standard code during the reporting period[87]. - The board believes that the current structure of having the chairman also serve as the CEO is beneficial for the company's business prospects and operational efficiency[90]. - The company has a set of director nomination policies that consider individual character, professional qualifications, skills, knowledge, and experience relevant to the group's business and strategy[92]. - The board is responsible for leading and monitoring the company, guiding and supervising its affairs, and ensuring good internal control and risk management systems[93]. - The company has received written annual confirmations of independence from all independent non-executive directors[91]. - The company will continue to review the effectiveness of its corporate governance structure to assess whether the roles of chairman and CEO should be separated[90]. - The independent non-executive directors account for one-third of the board, with at least one possessing appropriate professional qualifications or financial management expertise[91]. - The company has established written guidelines for employees regarding securities trading to prevent insider trading[87]. - The company has established three committees: Audit Committee, Remuneration and Nomination Committee, with specific written terms of reference for each[96]. - The Audit Committee held five meetings during the reporting period and reviewed the financial reporting procedures and internal control systems[97]. - The Remuneration and Nomination Committee reviewed the remuneration policies for directors and senior management, ensuring compliance with applicable regulations[98]. - The senior management's salary range for the year ended December 31, 2022, included one individual earning between HKD 2,000,001 and HKD 2,500,000, one earning between HKD 3,000,001 and HKD 5,000,000, and one earning between HKD 5,000,001 and HKD 6,000,000[99]. - The company provides liability insurance for directors and senior management against legal actions arising from company affairs[95]. - Continuous professional development is encouraged for all directors to ensure they remain informed about their responsibilities and relevant regulations[95]. - The Audit Committee reviewed related party transactions to ensure compliance with legal and regulatory requirements[97]. - The company has a policy for director remuneration that includes annual director fees and potential stock options or awards[100]. - The company ensures that all directors receive comprehensive onboarding to understand the business and operations effectively[95]. - The company conducts regular training sessions for directors on relevant laws and regulations to keep them updated[95]. - The board consists of 12 members, including 5 executive directors, 3 non-executive directors, and 4 independent non-executive directors, with a gender ratio of 3 female to 9 male directors[102]. - Employee gender distribution shows 53.78% male and 46.22% female, indicating a balanced gender diversity within the company[103]. - The company has established a nomination committee to evaluate the independence of independent non-executive directors and review the board's structure and diversity policies[101]. - The board's independence exceeds the Hong Kong Stock Exchange's requirements, with 4 out of 12 directors being independent non-executive directors[104]. - The company has implemented a whistleblowing policy to encourage reporting of misconduct, ensuring confidentiality and protection for whistleblowers[106]. - The company has developed compliance manuals and anti-corruption policies to enhance daily oversight capabilities against bribery and corruption[105]. - The board aims to maintain the current female representation and ultimately achieve gender equality[102]. - The nomination committee will review the board diversity policy annually and set measurable targets for achieving diversity[102]. - The board held eight meetings during the reporting period, ensuring active participation from directors[109]. - The company is committed to regular reviews of its anti-corruption policies and whistleblowing mechanisms to ensure effectiveness[106]. - The board emphasizes that corporate culture is the foundation for long-term business development and economic achievement[111]. - The company has appointed experienced professionals in key management positions to enhance its operational efficiency and strategic direction[84]. Risk Management and Compliance - The board is responsible for evaluating and determining the nature and extent of risks the company is willing to take to achieve strategic objectives, maintaining effective risk management and internal control systems[113]. - The company has implemented various risk management procedures and guidelines to identify risks affecting its business, including operational, financial, regulatory compliance, and data security risks[113]. - The board confirms that there are no significant uncertainties that may severely affect the company's ability to continue as a going concern[114]. - The company has maintained compliance with all relevant laws and regulations during the reporting period, with no significant violations reported[181]. - Related party transactions were conducted fairly and in accordance with legal regulations, with no actions found that harmed the company's or shareholders' interests[194]. - The independent auditor's report confirms that the consolidated financial statements fairly present the financial position and performance of the group as of December 31, 2022, in accordance with Hong Kong Financial Reporting Standards[197]. Shareholder Relations and Communication - The company encourages shareholders to participate in general meetings and has established procedures for calling extraordinary general meetings upon request from shareholders holding more than 10% of shares[117]. - The company has strengthened its cultural framework during the reporting period, focusing on respect, agility, innovation, quality first, and dedication as core values[111]. - The company has established multiple communication channels with shareholders, including annual and extraordinary general meetings, to enhance investor relations and transparency[122]. - All resolutions presented at the annual general meeting on June 29, 2022, and the extraordinary general meeting on December 21, 2022, were approved[122]. - The company allows shareholders holding more than 3% of shares to propose temporary motions 10 working days before the general meeting[118]. - The company’s articles of association were amended and approved by shareholders on June 29, 2022, with no significant changes since December 31, 2022[123]. - The company emphasizes timely and unfiltered disclosure of information to enable informed investment decisions by shareholders[121]. - The company’s communication policy is regularly reviewed to ensure effectiveness in addressing shareholder concerns[124]. Future Plans and Investments - The company plans to invest approximately RMB 2,244.7 million in the innovative vaccine industrial park project to enhance manufacturing capacity[65]. - The company plans to issue Global Depositary Receipts (GDR) and list them on the Swiss Stock Exchange to enhance international financing channels and brand image[129]. - The company is currently evaluating the issuance scale and fundraising purposes for the proposed GDR issuance[129]. - The company anticipates that the remaining balance of the A-share IPO proceeds will be fully utilized by the end of 2024[170]. - The company has allocated RMB 112.2 million for working capital and other general corporate purposes, reflecting a rise from RMB 5.5 million[166]. - The expected timeline for utilizing the remaining balance of the A-share IPO proceeds is by the end of 2024[168]. - The company has experienced delays in the progress of other major products due to resource allocation towards the Ad5-nCoV project[166]. - The company aims to enhance its vaccine product portfolio to improve market competitiveness[164].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6185） 截至2022年12月31日止的年度業績公告 康希諾生物股份公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈本公司及 其附屬公司截至2022年12月31日止年度之經審計合併年度業績。 本業績公告列載本公司截至2022年12月31日止年度報告全文，並符合香港聯合交 易所有限公司證券上市規則中有關年度業績初步公告須附載的資料之要求。董事 會及董事會下轄的審計委員會已審閱並確認本業績公告。 本業績公告於香港聯合交易所有限公司網站( www.hkexnews.hk)及本公司網站 ( www.cansinotech.com)刊登。本公司截至2022年12月31日止年度的年度報告將在 適當時候寄發予本公司股東，並於上述網站上刊登。 | --- | |------------- ...

Financial Performance - For the nine months ended September 30, 2022, the company's operating revenue attributable to shareholders was RMB 77,605 thousand, a decrease of 92.42% compared to the same period last year[3]. - The net profit attributable to shareholders for the same period was a loss of RMB 486,649 thousand, representing a decline of 222.65% year-on-year[3]. - Total revenue for the first three quarters of 2022 was RMB 707,395 thousand, a significant decrease from RMB 3,085,775 thousand in the same period of 2021, representing a decline of approximately 77%[19]. - Operating profit for the first three quarters of 2022 was a loss of RMB 645,593 thousand, compared to a profit of RMB 1,295,251 thousand in the same period of 2021[22]. - Net profit attributable to shareholders for the first three quarters of 2022 was a loss of RMB 488,682 thousand, while in 2021, it was a profit of RMB 1,333,896 thousand, indicating a substantial decline[24]. - The company reported a total comprehensive loss of RMB 488,626 thousand for the first three quarters of 2022, contrasting with a total comprehensive income of RMB 1,333,896 thousand in the same period of 2021[27]. Expenses and R&D - Research and development expenses totaled RMB 229,531 thousand, an increase of 111.18% compared to the same period last year, with R&D expenses accounting for 295.77% of operating revenue[3]. - The company paid RMB 489,173 thousand in cash to employees in the first three quarters of 2022, an increase from RMB 255,832 thousand in 2021[29]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 11,539,285 thousand, a decrease of 2.82% from the end of the previous year[4]. - The equity attributable to shareholders decreased by 9.74% to RMB 7,216,494 thousand compared to the previous year-end[4]. - Total liabilities as of September 30, 2022, amounted to RMB 3,784,224 thousand, an increase from RMB 3,326,303 thousand as of December 31, 2021[17]. - Current liabilities totaled RMB 2,770,161 thousand as of September 30, 2022, down from RMB 2,861,417 thousand at the end of 2021, reflecting a decrease of approximately 3.2%[15]. - Non-current liabilities increased to RMB 1,014,063 thousand as of September 30, 2022, compared to RMB 464,886 thousand at the end of 2021[17]. Cash Flow - The net cash flow from operating activities for the nine months was a loss of RMB 525,814 thousand, a decline of 240.05% year-on-year[3]. - Operating cash flow for the first three quarters of 2022 was negative at RMB (1,393,278) thousand, compared to a positive RMB 1,243,273 thousand in the same period of 2021[29]. - Cash inflow from investment activities increased significantly to RMB 9,360,944 thousand in 2022, up from RMB 3,968,365 thousand in 2021[30]. - Net cash flow from financing activities in 2022 was RMB 628,605 thousand, a decrease from RMB 1,397,063 thousand in 2021[30]. - The total cash and cash equivalents at the end of Q3 2022 were RMB 2,964,816 thousand, down from RMB 4,864,798 thousand at the end of Q3 2021[31]. - The company reported a significant increase in cash received from investment recoveries, totaling RMB 8,836,912 thousand in 2022 compared to RMB 3,936,000 thousand in 2021[30]. - The net cash flow from investment activities was negative at RMB (1,923,586) thousand in 2022, compared to RMB (2,233,144) thousand in 2021[30]. Market Conditions - The company attributed the significant decline in revenue and profit primarily to a sharp decrease in demand for COVID-19 vaccines and adjustments in product pricing[6]. - The company has identified a competitive market environment for COVID-19 vaccines, with a notable decrease in demand since 2021, leading to potential challenges in future sales[10]. - The company has conducted impairment tests on COVID-19 vaccine-related assets due to signs of impairment, reflecting a proactive approach to asset management in a changing market[10]. Shareholder Information - The top shareholder, HKSCC Nominees Limited, holds 39.63% of the total shares, with a total of 98,062,297 shares[9].